While the European Medicines Agency gave the world's first malaria vaccine a regulatory nod last July, the vaccine isn't perfect, conferring only partial immunity that wanes over time. On Monday, Bill Gates and Chancellor George Osborne, the British finance minister, announced a £3 billion fund ($4.28 billion) to support research and efforts to eradicate malaria.
Geneva-based Gavi, the global vaccine alliance funded by the Bill and Melinda Gates Foundation and other donors, has pledged $500 million over the next 5 years to support India's country-wide immunization program.
Louis Schofield, director of the Australian Institute of Tropical Health and Medicine at James Cook University, received a grant from the Bill & Melinda Gates Foundation worth AU$2.8 million to pursue preclinical development of a malaria vaccine.
China Daily posted an interview with Bill Gates, co-founder of Microsoft and co-chair of the Bill & Melinda Gates Foundation, who lauded the country's efforts to build on reforms that have transformed access to healthcare services in the world's most populous country.
While spending a summer in Peru after her sophomore year at Cornell University, Lauren Braun came up with an idea that could change the way parents in developing countries around the world remember their children's vaccination needs.
In late June, drug regulators from around the world gathered in Dar Es Salaam, Tanzania, to brainstorm solutions for solving a major problem in many African countries and other developing nations: a lack of access to veterinary care, and most importantly, to particular drugs and vaccines that could protect against livestock losses.
Japan's Eisai, Shinogi and Takeda Pharmaceutical have teamed up with U.K.-based AstraZeneca on a broad R&D; effort to find treatments for insect-borne parasitic diseases Chagas and leishmaniasis.
The virus peste des petits ruminants (PPR) isn't that well known in developed countries, but it is a plague in parts of Africa and Asia, where it kills up to 70% of the sheep and goats it infects. Now the United Nations Food and Agriculture Organization is launching a global campaign to wipe out PPR by 2030.
The Bill & Melinda Gates Foundation announced this week it's betting on CureVac, a move both Sanofi and Boehringer Ingelheim made last year, committing to an mRNA technology designed to make vaccines less expensive and easier to make.
In bid to improve patient adherence, the U.S. National Institutes of Health is funding and helping run two clinical trials of long-acting injectable HIV candidates being developed by Johnson & Johnson's Janssen and GlaxoSmithKline.